PMCB

PharmaCyte Biotech, Inc. (PMCB) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended January 31, 2026. PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer using its proprietary "Cell-in-a-Box" technology. The company's primary product candidate, CypCaps, is intended for locally advanced, inoperable pancreatic cancer (LAPC). The company is currently a Non-accelerated filer and a Smaller reporting company.

Operations are currently constrained by an FDA clinical hold on its Investigational New Drug (IND) application, which has been in place since October 2020. A reconstituted Board of Directors and a Business Review Committee are evaluating the company's strategy and its relationship with its technology licensor, SG Austria, leading to curtailed spending on development programs pending further review.

Key Financial Metrics

Note: Net income for the three months ended Jan 31, 2026, was driven by non-cash gains related to changes in the fair value of warrant liabilities and investments, offset by significant operating losses and preferred stock accretion.

Material Changes vs. Prior Period

• Operating Expenses: General and administrative (G&A) expenses increased significantly to $2.02 million for the quarter (up from $0.84 million in the prior year quarter) and $4.01 million for the nine-month period (up from $3.02 million). This increase is primarily due to stock-based compensation (RSUs granted to directors/CEO) and increased legal/professional fees related to capital raises.
• Other Income/Expense: The nine-month period ended Jan 31, 2026, resulted in a net other expense of $(10.7) million, a sharp reversal from the $22.2 million net other income in the prior year period. This is largely due to a loss on the change in fair value of warrant liabilities ($8.3 million) and a loss on the change in fair value of QCLS investments ($3.5 million), partially offset by a gain on the change in fair value of the Femasys note receivable ($1.3 million).
• Liquidity: Cash and cash equivalents increased by approximately $5.0 million during the nine-month period, driven by financing activities (Series C private placement) and investing activities (collection of Femasys note), despite operating cash outflows of $3.8 million.
• Liabilities: Total liabilities increased from $3.3 million to $16.5 million, primarily due to the recognition of warrant liabilities ($13.7 million) and derivative liabilities ($1.1 million) associated with the Series C preferred stock issuance.

Guidance, Outlook, Risks, and Unusual Items

• Capital Raise: In August 2025, the company completed a Series C private placement, raising $7.0 million in gross proceeds through the sale of convertible preferred stock and warrants. Net proceeds were approximately $6.2 million.
• Investments: In September 2025, the company invested $3.0 million in Q/C Technologies, Inc. (QCLS) Series H preferred stock and warrants. The company also settled a $5.0 million convertible note receivable from Femasys Inc. in full during the period.
• Regulatory Status: The FDA clinical hold remains in effect. The company has submitted updated data and is in dialogue with the FDA to lift the hold. Management believes current cash reserves (~$19 million) are sufficient for at least the next 12 months, but additional capital will be required to complete clinical trials.
• Nasdaq Compliance: The company received notice from Nasdaq on December 1, 2025, regarding non-compliance with the minimum bid price requirement ($1.00 per share). The company has 180 days (until June 1, 2026) to regain compliance, potentially through a reverse stock split.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding insufficient segregation of duties for the CFO and insufficient management review controls.
• Legal Settlement: A legal settlement with H.C. Wainwright & Co. was finalized in May 2025, involving a $1.55 million payment and the issuance of warrants.

Key Facts for Investor Verification

• FDA Clinical Hold: Verify the current status of the FDA clinical hold on the LAPC IND and the specific remaining requirements to lift it.
• SG Austria Relationship: Confirm the outcome of the Business Review Committee's evaluation of the relationship with SG Austria, the holder of the Cell-in-a-Box technology know-how.
• Nasdaq Delisting Risk: Monitor the stock price to ensure compliance with the $1.00 minimum bid price requirement by June 1, 2026, to avoid delisting.
• Warrant Liability Volatility: Note that a significant portion of the company's liabilities ($13.7 million) consists of warrant liabilities subject to fair value adjustments, which can cause significant volatility in reported net income/loss.
• Capital Runway: Assess the sufficiency of the ~$20 million cash balance against the estimated costs to complete preclinical studies and clinical trials, given the current spending curtailment.